Just three years ago, DNA testing company 23andMe was the golden child of Wall Street and Silicon Valley. Today, the firm is at risk of being delisted from the Nasdaq.
Source: ctv business
23andMe is low on cash and its stock is worth pennies. The CEO wants another chance

